* Denali Therapeutics Inc DNLI.OQ reported a quarterly
adjusted
loss of 68 cents per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -80 cents. The mean expectation of
sixteen analysts for the quarter was for a loss of 70 cents per
share. Wall Street expected results to range from -86 cents
to -53 cents per share.
* Reported revenue was zero; analysts expected $14.02
million.
* Denali Therapeutics Inc's reported EPS for the quarter was
a
loss of 68 cents.
* The company reported a quarterly loss of $101.8 million.
* Denali Therapeutics Inc shares had fallen by 16.5% this
quarter and lost 20.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 14.9%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Denali
Therapeutics Inc is $35.50
This summary was machine generated from LSEG data May 7 at 09:12
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.70 -0.68 Beat
Dec. 31 2023 -0.80 -0.86 Missed
Sep. 30 2023 -0.80 -0.72 Beat
Jun. 30 2023 -0.68 1.30 Beat